Langermann Sol 4
4 · NextCure, Inc. · Filed Apr 2, 2024
Insider Transaction Report
Form 4
NextCure, Inc.NXTC
Langermann Sol
Chief Scientific Officer
Transactions
- Award
Employee Stock Option (Right to Buy)
2024-03-29+93,900→ 93,900 totalExercise: $2.23Exp: 2034-03-28→ Common Stock (93,900 underlying)
Footnotes (1)
- [F1]The option vests in full on the one year anniversary of the grant, March 29, 2025.